What’s Next for Galmed Pharmaceuticals Ltd. (GLMD) After Today’s Huge Increase?

February 15, 2018 - By Vivian Currie

The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is a huge mover today! The stock increased 26.79% or $1.46 during the last trading session, reaching $6.91. About 628,943 shares traded or 649.06% up from the average. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 0.41% since February 15, 2017 and is uptrending. It has underperformed by 16.29% the S&P500.
The move comes after 7 months positive chart setup for the $87.99 million company. It was reported on Feb, 15 by Barchart.com. We have $7.12 PT which if reached, will make NASDAQ:GLMD worth $2.64 million more.

Analysts await Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to report earnings on March, 22. They expect $-0.23 EPS, up 42.50 % or $0.17 from last year’s $-0.4 per share. After $-0.23 actual EPS reported by Galmed Pharmaceuticals Ltd. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ratings Coverage

Among 5 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Galmed Pharmaceuticals Ltd had 8 analyst reports since August 14, 2015 according to SRatingsIntel. On Monday, July 31 the stock rating was maintained by Maxim Group with “Buy”. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) earned “Buy” rating by H.C. Wainwright on Monday, March 28. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 8. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) earned “Buy” rating by Roth Capital on Thursday, August 13. Maxim Group downgraded the stock to “Hold” rating in Wednesday, February 14 report.

More notable recent Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) news were published by: Seekingalpha.com which released: “Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2017 Results …” on May 15, 2017, also Seekingalpha.com with their article: “Galmed’s Aramchol flunks mid-stage NAFLD study” published on February 14, 2018, Prnewswire.com published: “Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting” on November 27, 2017. More interesting news about Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) were released by: Prnewswire.com and their article: “Galmed Pharmaceuticals Announces Pricing of Offering of Ordinary Shares to …” published on August 03, 2017 as well as Seekingalpha.com‘s news article titled: “Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff On Q3 2017 Results …” with publication date: November 09, 2017.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company has market cap of $87.99 million. The firm is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It currently has negative earnings. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.